Recent Articles
Assessing the FDA’s Breakthrough Drug Program After Six Years
In the first four years of the U.S. Food and Drug Administration’s (FDA) breakthrough-therapy designation program, the agency approved 31 “breakthrough” drugs, but many...
FDA Granted Selinexor Fast-Track Status
The U.S. Food and Drug Administration granted fast-track status to selinexor, an XPO1 inhibitor, for patients with heavily pretreated multiple myeloma (MM) who have...
Venetoclax Outperforms Standard Chemo-Immunotherapy in the Treatment of Relapsed/Refractory CLL
Treatment with the BCL2 inhibitor venetoclax and rituximab led to deeper and more durable responses than the combination of bendamustine and rituximab in patients...
Long-Term Follow-up Comparing Conditioning Regimens for Patients With AML Undergoing HCT
Nearly 10 years after allogeneic hematopoietic cell transplantation (HCT), patients with acute myeloid leukemia (AML) who received either reduced-intensity conditioning or myeloablative conditioning had...
Selinexor Plus Dexamethasone Active in Heavily Refractory Myeloma
In phase I trials, the first-in-class selective inhibitor of XPO1 selinexor (with or without low-dose dexamethasone) showed clinical activity against several types of hematologic...
Current Issue
April 2018, Volume 4, Issue 5
This issue features a look at the U.S. health-care system’s transition from a paper-based system to electronic health records, an introduction to a series about oncology nurse practitioners, and more.
